Skip to main content

What the FDA labels say about taking them together

Bortezomib and daratumumab/hyaluronidase

Daratumumab/hyaluronidase's FDA label of September 3, 2026 names bortezomib in its warnings and precautions section; the bortezomib labels PlainMeds reads (4) do not name daratumumab/hyaluronidase. The daratumumab/hyaluronidase label: “… light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone.”

Check it at the source: the bortezomib FDA label on DailyMed (effective February 27, 2023, Hospira, Inc.); the daratumumab/hyaluronidase FDA label on DailyMed (effective September 3, 2026).

What does the bortezomib label say about daratumumab/hyaluronidase?

Bortezomib's label (effective February 27, 2023) and its 3 other brand-application labels do not name daratumumab/hyaluronidase in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (BORTEZOMIB), Hospira, Inc., effective February 27, 2023 (SPL set 9fdf6169-699f-40eb-bda1-760253062b3c), via openFDA; the full label on DailyMed

What does the daratumumab/hyaluronidase label say about bortezomib?

Daratumumab/hyaluronidase label, warnings and precautions

Toxicity in Patients with Light Chain (AL) Amyloidosis Serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone [see Adverse Reactions (6.1) ].

Source: FDA drug label (Darzalex Faspro), Janssen Biotech, Inc., effective September 3, 2026 (SPL set 4bb241af-4299-4373-8762-2d6709515db0), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

22Bortezomib generic labelers
0Daratumumab/hyaluronidase generic labelers
BortezomibDaratumumab/hyaluronidase
Labeled forLeukemia, lymphoma and myelomaLeukemia, lymphoma and myeloma
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?